CN103656671A - Lentinan-adriamycin bonding medicine and preparation method thereof - Google Patents
Lentinan-adriamycin bonding medicine and preparation method thereof Download PDFInfo
- Publication number
- CN103656671A CN103656671A CN201310728210.8A CN201310728210A CN103656671A CN 103656671 A CN103656671 A CN 103656671A CN 201310728210 A CN201310728210 A CN 201310728210A CN 103656671 A CN103656671 A CN 103656671A
- Authority
- CN
- China
- Prior art keywords
- lentinan
- adriamycin
- bonding medicine
- adriamycin bonding
- amycin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
The invention provides a lentinan-adriamycin bonding medicine which has the structure shown in the formula (I) or formula (II) in the Specification, wherein n refers to the polymerization degree of lentinan, and is not less than 10 and not greater than 3278. According to the invention, lentinan and adriamycin are used as raw materials, or lentinan, sodium cyanoborohydride and adriamycin are used as raw materials to prepare two types of lentinan-adriamycin bonding medicines; as the lentinan used as the raw material has excellent biological activity and biocompatibility, and small toxic and side effects, the prepared lentinan-adriamycin bonding medicines have excellent biological activity and biocompatibility, and lower toxic and side effects; in addition, the lentinan and adriamycin are connected through oxime bonds, and can be quickly released in the tumor tissue or cells with the lower pH value, so that the efficacy of the lentinan-adriamycin bonding medicine is improved; the reduced lentinan-adriamycin bonding medicine which has the structure shown in the formula (II) in the Specification is more stable in performance, and the adriamycin can be released more slowly, so that the ideal long-acting treatment is realized.
Description
Technical field
The present invention relates to chemical bonding medicine technical field, relate in particular to a kind of lentinan-adriamycin bonding medicine and preparation method thereof.
Background technology
Amycin, have another name called 1,4-Hydroxydaunomycin, Isosorbide-5-Nitrae-hydroxyl rubidomycin, many Suo Rou compare star, Doxorubicin, is a kind of antitumor drug of anthracycline antibiotic class high-efficiency broad spectrum, and is a kind of Cell cycle non-specific medicine and acts on the strongest to the S phase, main by inserting cell DNA, thus initiation topoisomerase II destroys the tertiary structure of DNA and brings into play drug effect.Up to now, amycin is considered to a kind of strong clinical chemotherapy medicine, the entity tumors such as primary treatment hepatocarcinoma, pulmonary carcinoma, gastric cancer, breast carcinoma, ovarian cancer, bladder cancer, thyroid carcinoma.
At present, the chemotherapy of amycin is mainly brought into play drug effect by the mode of intravenously administrable clinically, yet the medicine whole body that distributes rapidly after intravenous injection, in addition the amycin half-life is shorter, and lack the targeting identification ability to tumor tissues, therefore can reach tumor locus and bring into play the amycin ratio of curative effect very low, cause its bioavailability not high, inefficiency, clinically can only frequent drug administration in order to maintain drug effect, this will cause larger toxic and side effects to the normal structure of health and organ, particularly heart, kidney.For addressing the above problem, the exploitation of amycin novel form is the focus of researcher research always, wherein, chemical bonding medicine is because drug encapsulation mode is more stable, drug release process is more lasting and pharmaceutical release time has obtained research comparatively widely more for a long time.
Publication number is that the Chinese patent of CN102406946A discloses a kind of polymer bond drug, first poly glycol monomethyl ether, carboxylated amycin derivant, 1-(3-dimethylamino-propyl)-3-ethyl-carbodiimide hydrochloride and N-hydroxy-succinamide are reacted in organic solvent, obtain reaction mixture, in reaction mixture, add again PLL or chitosan, after reaction, obtain high molecule adriamycin bonding medicine; Publication number is that the Chinese patent of 101234205A discloses a kind of high molecule adriamycin bonding medicine with target function, by two kinds of polyethylene glycol-polylactic acid block copolymer Hybrid assemblings, formed, the polylactic acid end of the chain of the first polyethylene glycol-polylactic acid block copolymer is connected with amycin, the Polyethylene Glycol end of the chain of the second polyethylene glycol-polylactic acid block copolymer is connected with lactose, has slow-release function; Lactose has target function, can realize the targeted of amycin, therefore, this adriamycin bonding medicine can be in tumor tissues slow release; But above-mentioned two kinds of bonding medicines are because the chemical bond of bonding macromolecular compound and drug molecule is too stable, thereby have that drug loading is low, the problems such as release lack of wisdom of amycin.Biomaterials(Vol.31, p1360-1371, 2010) a kind of carboxylated amycin that bonding poly glycol monomethyl ether and cis-3-carboxyl glutaconic anhydride are modified in the surface amino groups of polyamide-amide dendrimer is disclosed and the high molecule adriamycin bonding medicine that obtains, this bonding medicine can discharge fast under the acid condition of tumor tissues and cell, thereby realize the intelligent of drug release, but the carrier material that this bonding medicine is used is polyamide-amide dendrimer, its preparation process is loaded down with trivial details, and biocompatibility is poor, be unfavorable for the practical application of bonding medicine.
Summary of the invention
In view of this, the technical problem to be solved in the present invention is to provide a kind of lentinan-adriamycin bonding medicine and preparation method thereof, and the lentinan-adriamycin bonding medicine of preparation has good biocompatibility and pH response.
The invention provides a kind of lentinan-adriamycin bonding medicine, there is structure shown in formula (I) or formula (II):
Wherein, the degree of polymerization that n is lentinan, 10≤n≤3278.
The present invention also provides a kind of preparation method of lentinan-adriamycin bonding medicine, comprising:
The buffer solution that is dissolved with doxorubicin hydrochloride is mixed, reacted with lentinan, the lentinan-adriamycin bonding medicine of (I) structure that obtains thering is formula;
Or the buffer solution that is dissolved with doxorubicin hydrochloride is mixed, reacted with lentinan and sodium cyanoborohydride, the lentinan-adriamycin bonding medicine of (II) structure that obtains thering is formula.
Preferably, described buffer solution is acetate buffer solution.
Preferably, the pH value of described buffer solution is 2～7.
Preferably, the temperature of described reaction is 20 ℃～65 ℃.
Preferably, the time of described reaction is 12h～120h.
Preferably, the mol ratio of described lentinan and amycin is 0.01～1; The mol ratio of described sodium cyanoborohydride and amycin is 0～0.01.
Preferably, after described reaction, also comprise dialysis.
Preferably, the pH value of described dialysis is 5～8.5.
Preferably, the time of described dialysis is 24h～72h.
Compared with prior art, the invention provides a kind of lentinan-adriamycin bonding medicine, there is structure shown in formula (I) or formula (II), wherein, the degree of polymerization that n is lentinan, 10≤n≤3278.It is raw material that lentinan and amycin are take in the present invention, or take lentinan, sodium cyanoborohydride and amycin as raw material, two kinds of lentinan-adriamycin bonding medicines have been prepared, because raw material lentinan has good biological activity and biocompatibility, and toxic and side effects is little, therefore lentinan-the amycin of preparation has good biological activity, biocompatibility and lower toxic and side effects; Simultaneously, lentinan is connected by oxime key with amycin, under its pH value condition lower in tumor tissues or cell, can discharge fast, thereby enhancing drug effect, reduced form lentinan-the adriamycin bonding medicine with formula (II) structure also has more stable performance, release to amycin is slower, can reach desirable long-acting treatment; And itself also has good biological activity metabolite lentinan, there is the effects such as antiviral, antitumor, adjusting immunity, blood sugar lowering, antioxidation, for the treatment of disease, there is good synergism.
Accompanying drawing explanation
Fig. 1 is the hydrogen nuclear magnetic resonance spectrogram of lentinan-adriamycin bonding medicine of preparing of the embodiment of the present invention;
Fig. 2 is the cumulative release curve chart of the lentinan-adriamycin bonding medicine of the embodiment of the present invention 2 preparations;
Fig. 3 is the cumulative release curve chart of the lentinan-adriamycin bonding medicine of the embodiment of the present invention 6 preparations.
The specific embodiment
The invention provides a kind of lentinan-adriamycin bonding medicine, there is structure shown in formula (I) or formula (II):
Wherein, the degree of polymerization that n is lentinan, 10≤n≤3278.
It is raw material that lentinan and amycin are take in the present invention, or take lentinan, sodium cyanoborohydride and amycin as raw material, two kinds of lentinan-adriamycin bonding medicines have been prepared, because raw material lentinan has good biological activity and biocompatibility, and toxic and side effects is little, therefore lentinan-the amycin of preparation has good biological activity, biocompatibility and lower toxic and side effects; Simultaneously, lentinan is connected by oxime key with amycin, under its pH value condition lower in tumor tissues or cell, can discharge fast, thereby enhancing drug effect, reduced form lentinan-the adriamycin bonding medicine with formula (II) structure also has more stable performance, release to amycin is slower, can reach desirable long-acting treatment; And itself also has good biological activity metabolite lentinan, there is the effects such as antiviral, antitumor, adjusting immunity, blood sugar lowering, antioxidation, for the treatment of disease, there is good synergism.
Lentinan-adriamycin bonding medicine provided by the invention has the structure shown in formula (I) or formula (II), wherein, the degree of polymerization that n is lentinan, preferred, 10≤n≤3278, preferred, 20≤n≤2700; The number-average molecular weight of described lentinan is preferably 500g.mol
-1～5000000g.mol
-1, 700g.mol more preferably
-1～100000g.mol
-1, most preferably be 1000g.mol
-1～10000g.mol
-1; In the present invention, because the degree of polymerization of the raw material lentinan using is controlled, therefore, the molecular weight of the lentinan-adriamycin bonding medicine of preparation is controlled.
The present invention also provides a kind of preparation method of lentinan-adriamycin bonding medicine, comprising:
The buffer solution that is dissolved with doxorubicin hydrochloride is mixed, reacted with lentinan, the lentinan-adriamycin bonding medicine of (I) structure that obtains thering is formula;
Or the buffer solution that is dissolved with doxorubicin hydrochloride is mixed, reacted with lentinan and sodium cyanoborohydride, the lentinan-adriamycin bonding medicine of (II) structure that obtains thering is formula.
Described lentinan-the adriamycin bonding medicine with formula (I) structure is prepared in accordance with the following methods:
First doxorubicin hydrochloride is dissolved in and in buffer solution, obtains mixed solution; Described doxorubicin hydrochloride has structure shown in formula III:
Described buffer solution is preferably acetate buffer solution, is specially sodium acetate-hac buffer; The pH value of described buffer solution is preferably 2～7, and more preferably 4.5～5.5, most preferably be 4.8～5.5; The ratio of the quality of described doxorubicin hydrochloride and the volume of buffer solution is preferably 0.01g～1g:5mL.The present invention is preferred, under the condition of lucifuge, mixes, and the time of described mixing is preferably 10min～60min, more preferably 20min～40min.
Then the mixed solution of preparation is mixed, reacted with lentinan, can prepare the lentinan-adriamycin bonding medicine with formula (I) structure; Described lentinan has structure shown in formula IV:
Wherein, the degree of polymerization that n is lentinan, preferred, 10≤n≤3278, preferred, 20≤n≤2700; The number-average molecular weight of described lentinan is preferably 500g.mol
-1～5000000g.mol
-1, 700g.mol more preferably
-1～100000g.mol
-1, most preferably be 1000g.mol
-1～10000g.mol
-1; The mol ratio of described lentinan and amycin is preferably 0.01～1, and more preferably 0.05～1; Most preferably be 0.02～0.06; The temperature of described reaction is preferably 20 ℃～65 ℃, more preferably 30 ℃～60 ℃, most preferably is 40 ℃～50 ℃; The time of described reaction is preferably 12h～120h, and more preferably 36h～72h, most preferably is 48h～60h; Described reaction is preferably carried out under the condition of lucifuge, and is preferably air-proof condition.
After reaction finishes, lentinan-the adriamycin bonding medicine with formula (I) structure to preparation is purified, the present invention is preferred, adopt the method for dialysis to purify to lentinan-amycin, the present invention there is no specific (special) requirements to the method for described dialysis, it can be dialysis process well known to those skilled in the art, the present invention preferably adopts bag filter to dialyse, described bag filter is preferably the bag filter that molecular cut off is 5000Dalton～14000Dalton, 7000Dalton more preferably, the pH value of described dialysis is preferably 5～8.5, more preferably 6.0～8.0, most preferably be 6.5～7.8, the time of described dialysis is preferably 24h～72h, and more preferably 36～72h, most preferably is 40h～48h, concrete, first reaction system is carried out to pH value adjusting, preferably adopt sodium bicarbonate to regulate pH value of reaction system, then with bag filter, dialyse, excessive free amycin is dialysed, then filter and lyophilizing, can obtain lentinan-adriamycin bonding medicine sterling.
The aldehyde radical that is lentinan at the described lentinan-adriamycin bonding medicine with formula (I) structure and the amino generation oximation reaction of doxorubicin hydrochloride obtain.
Described lentinan-the adriamycin bonding medicine with formula (II) structure is prepared in accordance with the following methods:
First doxorubicin hydrochloride is dissolved in and in buffer solution, obtains mixed solution; Described buffer solution is preferably acetate buffer solution, is specially sodium acetate-hac buffer; The pH value of described buffer solution is preferably 2～7, and more preferably 4.5～5.5, most preferably be 4.8～5.5; The ratio of the quality of described doxorubicin hydrochloride and the volume of buffer solution is preferably 0.01g～1g:5mL.
Then the mixed solution of preparation is mixed, reacted with lentinan and sodium cyanoborohydride, can prepare the lentinan-adriamycin bonding medicine with formula (II) structure; Described sodium cyanoborohydride molecular formula is NaBH
3cN, its structure is suc as formula shown in (V):
The mol ratio of described lentinan and amycin is preferably 0.01～1, and more preferably 0.05～1; The mol ratio of described sodium cyanoborohydride and amycin is preferably 0.01～1, and more preferably 0.05～0.5; The temperature of described reaction is preferably 20 ℃～65 ℃, more preferably 30 ℃～60 ℃; The time of described reaction is preferably 12h～120h, more preferably 4h～72h.
After reaction finishes, lentinan-the adriamycin bonding medicine with formula (II) structure to preparation is purified, the present invention is preferred, adopt the method for dialysis to purify to lentinan-amycin, the present invention there is no specific (special) requirements to the method for described dialysis, it can be dialysis process well known to those skilled in the art, the present invention preferably adopts bag filter to dialyse, described bag filter is preferably the bag filter that molecular cut off is 5000Dalton～14000Dalton, the pH value of described dialysis is preferably 5～8.5, more preferably 6.0～8.0, most preferably be 6.5～7.8, the time of described dialysis is preferably 24h～72h, and more preferably 36h～72h, most preferably is 40h～48h, concrete, first reaction system is carried out to pH value adjusting, preferably adopt sodium bicarbonate to regulate pH value of reaction system, then with bag filter, dialyse, excessive free amycin is dialysed, then filter and lyophilizing, can obtain lentinan-adriamycin bonding medicine sterling.
At the described reduced form lentinan-adriamycin bonding medicine with formula (II) structure, for the aldehyde radical of lentinan and the amino generation oximation reaction of amycin, and oxime key is reduced under the existence of sodium cyanoborohydride, the reduced form lentinan-adriamycin bonding medicine of (II) structure that obtains thering is formula.
The present invention there is no specific (special) requirements to the source of described lentinan, sodium cyanoborohydride and doxorubicin hydrochloride, can be for generally commercially available.
Lentinan-adriamycin bonding medicine to preparation carries out magnetic resonance detection, and result shows, in the present invention, lentinan has prepared lentinan-adriamycin bonding medicine together with being bonded to by oximation reaction with amycin; The drug release situation of lentinan-adriamycin bonding medicine under different pH condition to preparation detects, and result shows, lentinan-adriamycin bonding medicine provided by the invention has good pH response.
The invention provides a kind of lentinan-adriamycin bonding medicine, there is structure shown in formula (I) or formula (II), wherein, the degree of polymerization that n is lentinan, 10≤n≤3278.It is raw material that lentinan and amycin are take in the present invention, or take lentinan, sodium cyanoborohydride and amycin as raw material, two kinds of lentinan-adriamycin bonding medicines have been prepared, because raw material lentinan has good biological activity and biocompatibility, and toxic and side effects is little, therefore lentinan-the amycin of preparation has good biological activity, biocompatibility and lower toxic and side effects; Simultaneously, lentinan is connected by oxime key with amycin, under its pH value condition lower in tumor tissues or cell, can discharge fast, thereby enhancing drug effect, reduced form lentinan-the adriamycin bonding medicine with formula (II) structure also has more stable performance, release to amycin is slower, can reach desirable long-acting treatment; And itself also has good biological activity metabolite lentinan, there is the effects such as antiviral, antitumor, adjusting immunity, blood sugar lowering, antioxidation, for the treatment of disease, there is good synergism.
In order to further illustrate the present invention, below in conjunction with embodiment, lentinan-adriamycin bonding medicine provided by the invention and preparation method thereof is described in detail.
In following embodiment, product quality * 100% that reaction yield=the actual product quality/theory obtaining obtains.Described acetate buffer solution is specially sodium acetate-hac buffer.
The acetate buffer solution of preparation pH=5, the buffer that respectively measures 5mL configuration is placed in respectively 8 round-bottomed flasks, in each flask, add respectively 0.05g doxorubicin hydrochloride, after lucifuge stirring and dissolving, again according to the amount ratio of table 1, in each flask, add lentinan and sodium cyanoborohydride, the number-average molecular weight of described lentinan is 4208g.mol
-1, then seal each reaction bulb, according to the reaction condition of table 1, lucifuge reaction 52h, after reaction finishes, with sodium bicarbonate solution, adjust each reactant liquor pH to 7.4, then the bag filter that is 7000Dalton with molecular cut off dialysis 48h, lyophilizing after filtering, obtain respectively lentinan-adriamycin bonding medicine, experimental result is in Table 1, table 1 is reaction condition and the productive rate of the lentinan-adriamycin bonding medicine of the embodiment of the present invention 1～8 preparation, wherein, i represents the mol ratio of lentinan and doxorubicin hydrochloride, j represents the mol ratio of sodium cyanoborohydride and doxorubicin hydrochloride.
Lentinan-adriamycin bonding medicine to preparation carries out magnetic resonance detection, testing result is shown in Fig. 1, Fig. 1 is the hydrogen nuclear magnetic resonance spectrogram of lentinan-amycin of preparing of the embodiment of the present invention, wherein, curve A is the hydrogen nuclear magnetic resonance spectrogram of the lentinan-amycin of embodiment 1 preparation, and curve B is the hydrogen nuclear magnetic resonance spectrogram of the reduced form lentinan-amycin of embodiment 5 preparations; As shown in Figure 1, the present invention has prepared lentinan-adriamycin bonding medicine.
Reaction condition and the productive rate of the lentinan-adriamycin bonding medicine of table 1 embodiment of the present invention 1～8 preparation
Embodiment 9～16
The acetate buffer solution of preparation pH=5, the buffer that respectively measures 5mL configuration is placed in respectively 8 round-bottomed flasks, according to the proportioning of table 2, in each flask, add respectively doxorubicin hydrochloride, after lucifuge stirring and dissolving, according to the amount ratio of table 2, in each flask, add lentinan and sodium cyanoborohydride again, the number-average molecular weight of described lentinan is 4208g.mol
-1then seal each reaction bulb, 40 ℃ of lucifuge reaction 52h, after reaction finishes, with sodium bicarbonate solution, adjust each reactant liquor pH to 7.4, then the bag filter that is 7000Dalton with molecular cut off dialysis 48h, lyophilizing after filtering, obtain respectively lentinan-adriamycin bonding medicine, experimental result is in Table 2, and table 2 is reaction condition and productive rates of the lentinan-adriamycin bonding medicine of the embodiment of the present invention 9～16 preparations, wherein, i represents the mol ratio of lentinan and doxorubicin hydrochloride, and j represents the mol ratio of sodium cyanoborohydride and doxorubicin hydrochloride.
Lentinan-adriamycin bonding medicine that table 2 embodiment of the present invention 9～16 prepares
Embodiment 17～24
PH data according to table 3 are prepared respectively acetate buffer solution, and measure 5mL and be placed in round-bottomed flask, in each flask, add respectively 0.05g doxorubicin hydrochloride, after lucifuge stirring and dissolving, again according to the amount ratio of table 3, in each flask, add lentinan and sodium cyanoborohydride, the number-average molecular weight of described lentinan is 4208g.mol
-1then seal each reaction bulb, 40 ℃ of lucifuge reaction 52h, after reaction finishes, with sodium bicarbonate solution, adjust each reactant liquor pH to 7.4, then the bag filter that is 7000Dalton with molecular cut off dialysis 48h, lyophilizing after filtering, obtain respectively lentinan-adriamycin bonding medicine, experimental result is in Table 3, and table 3 is reaction condition and productive rates of the lentinan-adriamycin bonding medicine of the embodiment of the present invention 17～24 preparations, wherein, i represents the mol ratio of lentinan and doxorubicin hydrochloride, and j represents the mol ratio of sodium cyanoborohydride and doxorubicin hydrochloride.
Reaction condition and the productive rate of the lentinan-adriamycin bonding medicine of table 3 embodiment of the present invention 17～24 preparations
Embodiment 25～32
The acetate buffer solution of preparation pH=5, the buffer that respectively measures 5mL configuration is placed in respectively 8 round-bottomed flasks, in each flask, add respectively 0.05g doxorubicin hydrochloride, after lucifuge stirring and dissolving, again according to the amount ratio of table 4, in each flask, add lentinan and sodium cyanoborohydride, the number-average molecular weight of described lentinan is 4208g.mol
-1, then seal each reaction bulb, at 40 ℃, under the reaction condition of lucifuge, response time according to table 4 reacts, after reaction finishes, with sodium bicarbonate solution, adjust each reactant liquor pH to 7.4, then the bag filter that is 7000Dalton with molecular cut off dialysis 48h, lyophilizing after filtering, obtain respectively lentinan-adriamycin bonding medicine, experimental result is in Table 4, table 4 is reaction condition and productive rates of the lentinan-adriamycin bonding medicine of the embodiment of the present invention 25～32 preparations, wherein, i represents the mol ratio of lentinan and doxorubicin hydrochloride, j represents the mol ratio of sodium cyanoborohydride and doxorubicin hydrochloride.
Reaction condition and the productive rate of the lentinan-adriamycin bonding medicine of table 4 embodiment of the present invention 25～32 preparations
Embodiment 33～40
The acetate buffer solution of preparation pH=5, the buffer that respectively measures 5mL configuration is placed in respectively 8 round-bottomed flasks, in each flask, add respectively 0.05g doxorubicin hydrochloride, after lucifuge stirring and dissolving, again according to the amount ratio of table 5, in each flask, add lentinan and sodium cyanoborohydride, the number-average molecular weight of described lentinan is 4208g.mol
-1, then seal each reaction bulb, 40 ℃ of lucifuge reaction 52h, after reaction finishes, according to the dialysis pH value data of table 5, with sodium bicarbonate solution, the pH value of reactant liquor is regulated, then the bag filter that is 7000Dalton with molecular cut off dialysis 48h, lyophilizing after filtering, obtain respectively lentinan-adriamycin bonding medicine, experimental result is in Table 5, table 5 is reaction condition and productive rates of the lentinan-adriamycin bonding medicine of the embodiment of the present invention 33～40 preparations, wherein, i represents the mol ratio of lentinan and doxorubicin hydrochloride, j represents the mol ratio of sodium cyanoborohydride and doxorubicin hydrochloride.
Reaction condition and the productive rate of the lentinan-adriamycin bonding medicine of table 5 embodiment of the present invention 33～40 preparations
Embodiment 41～48
The acetate buffer solution of preparation pH=5, the buffer that respectively measures 5mL configuration is placed in respectively 8 round-bottomed flasks, in each flask, add respectively 0.05g doxorubicin hydrochloride, after lucifuge stirring and dissolving, again according to the amount ratio of table 6, in each flask, add lentinan and sodium cyanoborohydride, the number-average molecular weight of described lentinan is 4208g.mol
-1, then seal each reaction bulb, 40 ℃ of lucifuge reaction 52h, after reaction finishes, with sodium bicarbonate solution, adjust each reactant liquor pH to 7.4, then according to the dialysis time in table 6, with the bag filter that molecular cut off is 7000Dalton, dialyse, lyophilizing after filtering, obtain respectively lentinan-adriamycin bonding medicine, experimental result is in Table 6, table 6 is reaction condition and productive rates of the lentinan-adriamycin bonding medicine of the embodiment of the present invention 41～48 preparations, wherein, i represents the mol ratio of lentinan and doxorubicin hydrochloride, j represents the mol ratio of sodium cyanoborohydride and doxorubicin hydrochloride.
Reaction condition and the productive rate of the lentinan-adriamycin bonding medicine of table 6 embodiment of the present invention 41～48 preparations
Wherein, embodiment 41 and 45, because dialysis time is too short, failing dialyses completely removes free amycin, and lentinan-amycin purity of preparation is lower.
Embodiment 49～53
The acetate buffer solution of preparation pH=5, the buffer that respectively measures 5mL configuration is placed in respectively 8 round-bottomed flasks, in each flask, add respectively 0.05g doxorubicin hydrochloride, after lucifuge stirring and dissolving, again according to the amount ratio of table 7, in each flask, add lentinan and sodium cyanoborohydride, the number-average molecular weight of described lentinan is 4208g.mol
-1then seal each reaction bulb, 40 ℃ of lucifuge reaction 52h, after reaction finishes, with sodium bicarbonate solution, adjust each reactant liquor pH to 7.4, the bag filter that is 7000Dalton with molecular cut off dialysis 48h, lyophilizing after filtering, obtain respectively lentinan-adriamycin bonding medicine, experimental result is in Table 7, and table 7 is reaction condition and productive rates of the lentinan-adriamycin bonding medicine of the embodiment of the present invention 49～53 preparations, wherein, i represents the mol ratio of lentinan and doxorubicin hydrochloride, and j represents the mol ratio of sodium cyanoborohydride and doxorubicin hydrochloride.
Reaction condition and the productive rate of the lentinan-adriamycin bonding medicine of table 7 embodiment of the present invention 49～53 preparations
Embodiment 54～63
The acetate buffer solution of preparation pH=5, the buffer that respectively measures 5mL configuration is placed in respectively 8 round-bottomed flasks, in each flask, add respectively 0.05g doxorubicin hydrochloride, after lucifuge stirring and dissolving, again according to the amount ratio of table 8, in each flask, add lentinan and sodium cyanoborohydride, the number-average molecular weight of described lentinan is in Table 8, then seal each reaction bulb, 40 ℃ of lucifuge reaction 52h, after reaction finishes, with sodium bicarbonate solution, adjust each reactant liquor pH to 7.4, with the bag filter 48h that dialyses, the molecular cut off of bag filter is in Table 8, after dialysis finishes, filter and lyophilizing, obtain respectively lentinan-adriamycin bonding medicine, experimental result is in Table 8, table 8 is reaction condition and productive rates of the lentinan-adriamycin bonding medicine of the embodiment of the present invention 54～63 preparations, wherein, i represents the mol ratio of lentinan and doxorubicin hydrochloride, j represents the mol ratio of sodium cyanoborohydride and doxorubicin hydrochloride.
Reaction condition and the productive rate of the lentinan-adriamycin bonding medicine of table 8 embodiment of the present invention 54～63 preparations
Embodiment 64
Lentinan-the adriamycin bonding medicine of embodiment 2 and embodiment 6 preparations in the situation that being 4.0,5.0,6.8,7.4, pH value is carried out respectively to drug release, the results are shown in Figure 2 and Fig. 3, Fig. 2 is the cumulative release curve of the lentinan-adriamycin bonding medicine of the embodiment of the present invention 2 preparations, and Fig. 3 is the cumulative release curve of the lentinan-adriamycin bonding medicine of the embodiment of the present invention 6 preparations.
In Fig. 2, lentinan-amycin that curve a, b, c, d are respectively embodiment 2 preparations is respectively at pH value the percentage composition curve that the bonding medicine recording under 4.0,5.0,6.8,7.4 conditions discharges amycin, pH is lower as seen from Figure 2, the release of amycin is faster, illustrate that this bonding medicine has good pH response, the amycin being bonded on lentinan can discharge fast under the pH of tumor tissues or tumor cell condition, thereby strengthens effect of drugs.
In Fig. 3, reduced form lentinan-amycin of preparing for embodiment 6 is respectively at pH value the percentage composition curve that the bonding medicine recording under 4.0,5.0,6.8,7.4 conditions discharges amycin, pH changes reduced form lentinan-adriamycin bonding medicine impact very little as seen from Figure 3, illustrate that its release to amycin is slower, drug effect is longer.
From above-described embodiment, the present invention be take lentinan, sodium cyanoborohydride and amycin as raw material, has prepared lentinan-adriamycin bonding medicine, has good pH response.
The explanation of above embodiment is just for helping to understand method of the present invention and core concept thereof.It should be pointed out that for those skilled in the art, under the premise without departing from the principles of the invention, can also carry out some improvement and modification to the present invention, these improvement and modification also fall in the protection domain of the claims in the present invention.
Claims (10)
1. lentinan-adriamycin bonding medicine, has structure shown in formula (I) or formula (II):
Wherein, the degree of polymerization that n is lentinan, 10≤n≤3278.
2. a preparation method for lentinan-adriamycin bonding medicine, comprising:
The buffer solution that is dissolved with doxorubicin hydrochloride is mixed, reacted with lentinan, the lentinan-adriamycin bonding medicine of (I) structure that obtains thering is formula;
Or the buffer solution that is dissolved with doxorubicin hydrochloride is mixed, reacted with lentinan and sodium cyanoborohydride, the lentinan-adriamycin bonding medicine of (II) structure that obtains thering is formula.
3. method according to claim 2, is characterized in that, described buffer solution is acetate buffer solution.
4. method according to claim 2, is characterized in that, the pH value of described buffer solution is 2～7.
5. method according to claim 2, is characterized in that, the temperature of described reaction is 20 ℃～65 ℃.
6. method according to claim 2, is characterized in that, the time of described reaction is 12h～120h.
7. method according to claim 2, is characterized in that, the mol ratio of described lentinan and amycin is 0.01～1; The mol ratio of described sodium cyanoborohydride and amycin is 0～0.01.
8. method according to claim 2, is characterized in that, also comprises dialysis after described reaction.
9. method according to claim 8, is characterized in that, the pH value of described dialysis is 5～8.5.
10. method according to claim 8, is characterized in that, the time of described dialysis is 24h～72h.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310728210.8A CN103656671B (en) | 2013-12-25 | 2013-12-25 | Lentinan-adriamycin bonding medicine and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310728210.8A CN103656671B (en) | 2013-12-25 | 2013-12-25 | Lentinan-adriamycin bonding medicine and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103656671A true CN103656671A (en) | 2014-03-26 |
| CN103656671B CN103656671B (en) | 2015-09-16 |
Family
ID=50296225
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310728210.8A Active CN103656671B (en) | 2013-12-25 | 2013-12-25 | Lentinan-adriamycin bonding medicine and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103656671B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110251515A (en) * | 2019-07-22 | 2019-09-20 | 天津国际生物医药联合研究院有限公司 | A kind of preparation method and application of Rho kinase inhibitor Y27632 load Lentinan compound |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102988999A (en) * | 2012-05-09 | 2013-03-27 | 中国药科大学 | Curcumin-polysaccharide conjugate as well as preparation method and application thereof |
-
2013
- 2013-12-25 CN CN201310728210.8A patent/CN103656671B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102988999A (en) * | 2012-05-09 | 2013-03-27 | 中国药科大学 | Curcumin-polysaccharide conjugate as well as preparation method and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| 许维国等: ""肟键连接的酸敏感葡聚糖–阿霉素键合药的合成及其表征"", 《2013年全国高分子学术论文报告会》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110251515A (en) * | 2019-07-22 | 2019-09-20 | 天津国际生物医药联合研究院有限公司 | A kind of preparation method and application of Rho kinase inhibitor Y27632 load Lentinan compound |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103656671B (en) | 2015-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103357022B (en) | Bifunctional polyethylene glycol and adriamycin conjugate and preparation method thereof | |
| CN103341177B (en) | Reduction sensitive type polyethylene glycol-medicament conjugate and preparation method thereof | |
| CN102406946B (en) | High molecular adriamycin bonded medicament and preparation method thereof | |
| CN102596178B (en) | Liposome having inner water phase containing sulfobutyl ether cyclodextrin salt | |
| CN102475891A (en) | PH-responsive polyethylene glycol-anticarcinogen conjugate, and synthetic method and application thereof | |
| CN103656670B (en) | Glucan-adriamycin conjugate drug and preparation method thereof | |
| CN102863627A (en) | Cisplatin complex and preparation method thereof | |
| CN103638530B (en) | Alginic acid-adriamycin bonding medicine and preparation method thereof | |
| CN103656671B (en) | Lentinan-adriamycin bonding medicine and preparation method thereof | |
| CN103656672B (en) | Hyaluronic acid-adriamycin bonding medicine and preparation method thereof | |
| CN102935237A (en) | Doxorubicin bonding medicine and preparation method thereof | |
| CN113461754B (en) | Base-modified adriamycin prodrug and preparation method and application thereof | |
| CN104001184B (en) | High molecule adriamycin bonding medicine and preparation method thereof | |
| CN104415342A (en) | Self-assembled drug carrier microcapsule system containing polypyrrolidone | |
| CN102895669A (en) | Cis-platinum complex and preparation method thereof | |
| CN102499986B (en) | Macromolecule-cis-platinum compound, preparation method and application thereof | |
| CN105169405A (en) | Preparation method of adriamycin polymer drug | |
| CN108578712A (en) | A kind of polymer-drug conjugate and preparation method thereof | |
| CN104415003A (en) | Polymer nano drug microcapsule containing polypyrrolidone | |
| CN110559449B (en) | Polygossypol prodrug micelle and preparation method thereof | |
| CN104414999A (en) | Anti-tumor targeted nanometer drug-loaded microcapsule preparation method | |
| CN103432591B (en) | Nano-micelle medicine using ethylene epoxide polymer as a carrier and a preparation method thereof | |
| CN104958769A (en) | Oxidized dextran-bortezomib-adriamycin bonded chemical and preparation method thereof | |
| CN105687135A (en) | Hybrid subtype tumor targeted nano-micelle and purpose thereof | |
| CN104434794A (en) | Novel adriamycin tumor cell inhibiting micelle preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |